Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420048 | 0.84 | EGFR (0.67) | EGFRKDR | |
| SCHEMBL5496194 | 0.83 | KDR (0.67) | EGFRKDR | |
| SCHEMBL4429258 | 0.82 | EGFR (0.65) | EGFRKDR | |
| SCHEMBL5498160 | 0.82 | EGFR (0.62) | EGFRKDR | |
| SCHEMBL5496186 | 0.82 | EGFR (0.62) | EGFRKDR | |
| SCHEMBL4430065 | 0.82 | EGFR (0.68) | EGFRKDR | |
| SCHEMBL4425294 | 0.82 | KDR (0.70) | EGFRKDR | |
| SCHEMBL5495617 | 0.82 | EGFR (0.61) | EGFRKDR | |
| SCHEMBL4690287 | 0.81 | EGFR (0.56) | EGFRKDR | |
| SCHEMBL4690072 | 0.81 | EGFR (0.54) | EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296973-B1 | GUANIDINE DERIVATIVES OF QUINAZOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-7001904-B1 | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | disclosed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |